Ambrosia Biosciences
CO - BoulderBiotechnology
Focus: Ambrosia Biosciences is a publicly listed biotechnology company founded in 2018, focused on oral small molecules targeting Class B GPCRs with a specialty in gastroenterology. The company operates as a mid-cap biotech with a Boulder, Colorado headquarters.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$130M
Open Jobs
0
About Ambrosia Biosciences
AI assessmentNot HiringNo open roles listed right now. Follow Ambrosia Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Solgar No7 Complex
Osteoarthritis, KneeClinical Trials (1)
NCT03442153Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee
N/AHelp build intelligence for Ambrosia Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.